Web Toolbar by Wibiya
Login | Sign Up AnonymousUser
twiter
New to Comunitee?


or Sign Up with Email

Business

>> CANTOR FITZGERALD Latest News

JUN 07, 2013 - Benzinga

A Must Read - Share

UPDATE: Cantor Fitzgerald Initiates Coverage on Myriad Genetics on Position in Molecular Diagnostic Franchises

In a report published on Friday, analysts at Cantor Fitzgerald initiated coverage on Myriad Genetics (NASDAQ: MYGN) with a Buy rating and $40 PT. In the report, lead analyst Sung Ji Nam commented that, "We are initiating coverage of MYGN with a BUY rating and $40 PT.

Tags: UPDATE: Cantor Fitzgerald Initiates Coverage on Myriad Genetics on Position in Molecular Diagnostic Franchises,  Cantor Fitzgerald Latest News